Glucagon-like peptide-1 receptor agonists (GLP1-RA) have been shown to be associated with improved cardiovascular outcomes, weight loss, and reduced inflammation and may be considered as first-line therapy in patients with PsA and diabetes or obesity [119,120]. Here, GLP1R is linked to obesity disorder.